A PSEN2 genetic test checks for disease-causing changes in the PSEN2 gene, which provides instructions for presenilin 2, when memory or thinking symptoms progress before age 65. The early-onset panel confirms diagnosis in symptomatic people with about 60-80% clinical sensitivity, so preparation means counseling and testing the affected relative first, and next steps mean cascade testing for relatives.
PSEN2 changes are a rare cause of early-onset Alzheimer's disease. At least 11 mutations cause disease and account for less than 5% of early-onset cases. Testing is most useful when symptoms started before 65 and a dominant family pattern is present.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What a PSEN2 result means
- How accurate is testing as symptoms progress?
- How should families prepare?
- What are the next steps after testing?
What a PSEN2 result means
PSEN2 is one of three rare single-gene causes of early-onset Alzheimer's disease. According to the National Institute on Aging, the three genes are APP on chromosome 21, PSEN1 on chromosome 14, and PSEN2 on chromosome 1 in its Alzheimer's genetics fact sheet. Disease mutations disrupt processing of amyloid precursor protein. That disruption causes overproduction of amyloid beta peptide, which collects in harmful brain plaques.
According to MedlinePlus Genetics, Asn141Ile and Met239Val are among the most common PSEN2 mutations in its PSEN2 gene page. Inheritance is autosomal dominant. Each child of a carrier has a 50/50 chance of inheriting the altered gene. Published joint guidelines from the American College of Medical Genetics and National Society of Genetic Counselors list penetrance near 95%, with onset often in the 40s to 70s but not precisely predictable.
How accurate is testing as symptoms progress?
Early-onset panels use massively parallel sequencing to confirm diagnosis in symptomatic people and to test at-risk relatives. According to ARUP Consult, the panel should not be ordered when symptoms began after age 65 in its early-onset panel fact sheet. Clinical sensitivity is about 60-80% in people diagnosed before age 65. A positive PSEN2 finding supports a genetic diagnosis.
A negative result does not exclude a heritable form of early-onset disease. Progression alone does not fix accuracy. Timing, age at onset, family history, and whether the tested person is symptomatic matter more. Testing the affected family member first gives the clearest result for others to use.
How should families prepare?
Obtain pre-test and post-test genetic counseling. Counseling covers consent, possible results, insurance effects, and plans for sharing results with relatives. It also helps decide whether broader early-onset testing fits the clinical picture.
Ask the care team about sample type, lab choice, and result timing. Bring a symptom timeline with age at onset. Bring a three-generation family history with ages, diagnoses, and causes of death when known.
- Confirm symptoms began before age 65 and testing is appropriate
- Schedule pre-test counseling before blood or saliva collection
- Test the affected relative first when possible
- Plan how positive, negative, and uncertain results will guide care
What are the next steps after testing?
Offer cascade testing to at-risk relatives when a PSEN2 mutation is found. Relatives can then make informed choices about predictive testing, family planning, and long-term care planning. When no mutation is found but suspicion remains high, ask about further evaluation and research options.
Consider referral to the Dominantly Inherited Alzheimer Network. According to the Dominantly Inherited Alzheimer Network, enrolled participants can receive clinical counseling and testing at no cost through the study in its enrolled-participant testing page. The network also studies prevention treatments for dominantly inherited disease.
